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prostate cancer cells support osteoclastogenesis
via a Runx2/Smad 5/receptor activator of NF-κB
ligand signaling axis
Aditi Gupta1, Wei Cao2 and Meenakshi A Chellaiah1*Abstract
Background: Bone loss and pathological fractures are common skeletal complications associated with androgen
deprivation therapy and bone metastases in prostate cancer patients. We have previously demonstrated that
prostate cancer cells secrete receptor activator of NF-kB ligand (RANKL), a protein essential for osteoclast
differentiation and activation. However, the mechanism(s) by which RANKL is produced remains to be determined.
The objective of this study is to gain insight into the molecular mechanisms controlling RANKL expression in
metastatic prostate cancer cells.
Results: We show here that phosphorylation of Smad 5 by integrin αvβ3 and RUNX2 by CD44 signaling,
respectively, regulates RANKL expression in human-derived PC3 prostate cancer cells isolated from bone metastasis.
We found that RUNX2 intranuclear targeting is mediated by phosphorylation of Smad 5. Indeed, Smad5
knock-down via RNA interference and inhibition of Smad 5 phosphorylation by an αv inhibitor reduced RUNX2
nuclear localization and RANKL expression. Similarly, knockdown of CD44 or RUNX2 attenuated the expression of
RANKL. As a result, conditioned media from these cells failed to support osteoclast differentiation in vitro.
Immunohistochemistry analysis of tissue microarray sections containing primary prostatic tumor (grade2-4) detected
predominant localization of RUNX2 and phosphorylated Smad 5 in the nuclei. Immunoblotting analyses of nuclear
lysates from prostate tumor tissue corroborate these observations.
Conclusions: Collectively, we show that CD44 signaling regulates phosphorylation of RUNX2. Localization of RUNX2
in the nucleus requires phosphorylation of Smad-5 by integrin αvβ3 signaling. Our results suggest possible
integration of two different pathways in the expression of RANKL. These observations imply a novel mechanistic
insight into the role of these proteins in bone loss associated with bone metastases in patients with prostate cancer.
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Prostate cancer is the most prevalent non-skin cancer to
affect men and it is the second leading cause of cancer-
related deaths in Western males [1,2]. The majority of
the patients with advanced prostate cancer will eventu-
ally develop bone metastases [3]. Prostate cancer cells
that metastasize to bone have the capacity to produce* Correspondence: mchellaiah@umaryland.edu
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reproduction in any medium, provided the orosteolytic lesions which are due to activation of osteo-
clasts [4]. Likewise, bone loss is increasingly recognized
as a common occurrence in men diagnosed with pros-
tate cancer receiving androgen deprivation therapy
(ADT). The receptor activator of nuclear factor kB lig-
and (RANKL) is an essential cytokine required for the
formation and activation of osteoclasts [5-7]. The in-
volvement of RANKL in the progression of prostate
tumor growth within bone and the subsequent bone loss
has been recently established in animal models of cancer
metastasis [8-13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tory role in osteoblast differentiation, is also highly
expressed in bone metastatic breast and prostate cancer
cells [14-16]. RUNX2 increases the oncogenic potential
through regulation of genes (e.g. MMP2, MMP9, and
MMP13) involved in metastasis and invasion of prostate
and breast cancer cells [17-19]. RUNX2 expression in
cancer cells facilitates the interaction between tumor
cells and the bone microenvironment that lead to osteo-
lytic disease [15,20]. For instance, in vivo blockade of the
Runx2-Indian hedgehog pathway in MDA-MB-231 cells
by targeting Runx2 with short hairpin RNA prevented
osteolytic disease [21]. Furthermore, the presence of pu-
tative binding sites for RUNX2 in the promoter region
of RANKL [22] and a striking decrease in the number of
osteoclasts in RUNX2- (Cbfa1-) deficient mice [22] sug-
gest that RUNX2 is potentially involved in RANKL
expression.
Smads, a family of proteins involved in the transloca-
tion of signals from receptors to the nucleus have been
shown to physically interact with RUNX2 [23]. Inter-
action between these proteins results in the formation of
transcriptionally active complexes which hold the poten-
tial to regulate various developmental and biological pro-
cesses [24,25]. In fact, cooperation between Smads and
RUNX2 induces osteoblast specific gene expression in
mesenchymal stem cells to promote osteoblast differenti-
ation [24,26,27]. The role of RUNX2 and Smads has been
extensively studied in a variety of cell systems. However,
the combined roles of these proteins and their signaling
mechanisms on RANKL expression in bone metastatic
prostate cancer cells have been largely unexplored.
Integrin αvβ3 and CD44 signaling have been shown to
increase the metastatic potential of cancer cells [28-30].
Integrin αvβ3 expression in tumor cells accelerates the
development of osteolytic lesions [31]. Integrin αvβ3 sig-
naling has been implicated in the expression of RANKL
and osteoclastogenesis by breast cancer in the bone
microenvironment [32]. CD44 signaling increases the
metastatic potential of prostate cancer cells [33,34].
Altered levels of CD44 have been seen in many epithelial
neoplasms and expression of CD44 has been shown to
carry prognostic implications [35,36]. RUNX2 expression
is regulated by CD44 signaling [37]. A neutralizing anti-
body to CD44s significantly decreased the expression of
Runx2 mRNA in hypertrophic chondrocytes [37]. CD44
signaling is a determinant of inflammatory bone loss
through expression of RANKL [38,39]. PC3 and LNCaP
cell lines have been used by many researchers to docu-
ment the role of CD44 in the metastatic process [40-43].
We have previously demonstrated that osteopontin regu-
lates the expression and secretion of RANKL in PC3 cells
[28]. However, the molecular mechanisms underlying the
expression of RANKL are not fully understood. The roleof multiple receptor signaling pathways (for e.g. CD44 and
integrin αvβ3) converge on the transcriptional factor(s) to
regulate RANKL expression needs further elucidation.
Therefore, our aim is to further elucidate the mechan-
isms by which RANKL expression is regulated by testing
the hypothesis that integrin αvβ3 and CD44 signaling
plays a key role in mediating the expression of RANKL.
Understanding the molecular mechanisms underlying
RANKL expression may provide a valuable insight into
the process of osteoclast differentiation and the resultant
bone resorptive activities within the skeletal microenvir-
onment. In the present study, the cooperative role of
RUNX2 and Smad5 in the expression of RANKL was
studied in PC3 cells. Here, we provide compelling evi-
dence that a) CD44 signaling regulates the phosphoryl-
ation of RUNX2; b) CD44 knockdown reduced RUNX2
phosphorylation, but not Smad 5 phosphorylation; c)
knockdown of Smad 5 levels or suppression of phosphor-
ylation of Smad 5 by an inhibitor to integrin αv reduced
nuclear localization of RUNX2, and d) inhibition of phos-
phorylation of either RUNX2 or Smad 5 reduces the ex-
pression of RANKL and osteoclast differentiation.
Results
We have primarily used PC3 cells derived from bony
metastasis for various analyses. We have also used pros-
tate cancer cells derived from brain (DU145) and lymph
node (LNCaP) metastases for comparative analyses. Nor-
mal prostatic epithelial (HPR1) and benign prostatic
hyperplasic (BPH) cells were used as controls.
RUNX2 expression is markedly increased in bone
metastatic prostate cancer cells
We initially examined the levels of RUNX2 expression in
PC3 and control (HPR1 and BPH) cell lines (Figure 1A).
RUNX2 expression was considerably higher at mRNA
(Figure 1A, lane 1) and protein (B, lane 1) levels as com-
pared with other control cell lines tested (A and B; lanes
2 and 3).
RUNX2 ablation reduces RANKL expression
RUNX2 is linked to MMP9 and RANKL expression
[44,45]. First, we attempted to determine the efficient dose
of SiRNA to RUNX2 to knockdown RANKL. The knock-
down of Runx2 by RNA interference decreases MMP9 ex-
pression [44]. Therefore, we have assessed the effects of
different doses (10, 25, 50nM) of RUNX2 SiRNA nucleo-
tide on the expression of MMP9 and MMP2 at mRNA
and protein levels (Additional file 1: Figure S1). RT-PCR
analysis demonstrated dose-dependent decrease in the ex-
pression of MMP9 at mRNA level and not MMP2. The
decrease was maximal at 50nM (>90%; Additional file 1:
Figure S1A). A significant decrease in the expression of
MMP9 and not MMP2 protein was observed with 50nM
Figure 1 Analysis of expression of RUNX2 and RANKL in PC3 cells. A and B. RT-PCR and immunoblotting analysis of expression of RUNX2 in
PC3 (lanes 1), HPR1 (lane 2) and BPH (lane 3) cells is shown. C-E: The effects of SiRNA to RUNX2 on RUNX2 (C) and RANKL (D) protein levels in total
cellular lysates (C and D) and conditioned medium (E). Immunoblotting analysis in conditioned medium represents the secreted levels of RANKL.
Untransfected (−) or scrambled SiRNA (Sc) transfected PC3 cells were used as controls (B-E). GAPDH was used as a loading control for RT-PCR (A)
and Western blot (B -D) analyses. The loading control for the conditioned medium is shown by the use of Coomassie blue staining of the blot (F).
G - I: Immunostaining and confocal microscopy analysis of distribution of RUNX2 (red; H) and RANKL (green; I) in PC3 cells. Distribution of both
RANKL (red) and RUNX2 (green) are shown in panel G. Results shown are representative of three independent experiments. Scale bar: 50 μm.
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Therefore, in further experiments, PC3 cells were trans-
fected with 50nM SiRNA nucleotides to RUNX2. Im-
munoblotting analysis shows the silencing effect >80% at
50nM SiRNA on RUNX2 protein level (Figure 1C, lane 3).
Subsequently, we determined the effects of RUNX2
knockdown on the expression of RANKL in PC3 cells
treated with 50nM SiRNA. RUNX2 ablation reduces total
cellular and secreted (Figure 1D and E, lane 3) RANKL
to a significant level (>85%). Secreted RANKL was deter-
mined in the conditioned medium (E and F). Untrans-
fected ((−); C-F, lane 1) and ScSiRNA (50nM; lane 2 in
C-F) transfected PC3 cells were used as controls.
Differential intracellular localization of RANKL and RUNX2
in PC3 cells
We examined the cellular distribution of RANKL and
RUNX2 by immunostaining and confocal analyses in
PC3 cells (Figure 1G-I). Diffuse and punctate distribu-
tion of RANKL (green) and RUNX2 (red) was observed.
RUNX2 distribution was observed in the perinuclear
and nuclear region. Lateral confocal sectioning and XZ
scanning of PC3 cells displayed distribution of RANKL
throughout cytoplasm and membrane (data not shown).
Colocalization of RANKL and RUNX2 was negligible.
Differential subcellular localization of these proteins may
be important for their function.ChIP analysis of Runx2-binding sites in the RANKL
promoter
Two sets of primers specific for RUNX2 binding sites on
RANKL promoter were used to detect the DNA frag-
ment (153 bp; Figure 2A, lanes 2 and 4) positioned be-
tween nucleotide −143 and −300 in human RANKL
promoter [46]. This fragment encompasses the RUNX2
binding site located between −228 to −234 nucleotides.
RT-PCR analysis demonstrated the expected product of
153 bp DNA fragment which suggests direct binding of
RUNX2 to the RANKL promoter (Figure 2A, lanes 2
and 4).
Ablation of RUNX2 reduces osteoclast differentiation
To analyze whether RUNX2 knockdown in PC3 cells
would modulate osteoclast differentiation, conditioned
media (CM; 50-100 μg protein) from PC3 cells untreated
(Figure 2B) or treated with scrambled (C) and SiRNA (D)
to RUNX2 were incubated with mouse bone marrow cells
in the presence of mCSF1 to induce osteoclast differenti-
ation in vitro. As shown in Figure 2, CM from PC3 cells
untransfected (B) or transfected with scrambled SiRNA to
RUNX2 induces differentiation of bone marrow cells to
mature osteoclasts. Conversely, osteoclast differentiation
was prevented by CM from PC3 cells knockdown of
RUNX2 (D) suggesting that RUNX2 regulates RANKL
expression, and that secretion of RANKL by metastatic
Figure 2 Analysis of binding of RUNX2 with RANKL promoter
and the effect of RUNX2 knockdown on osteoclast
differentiation. A. Chromatin immunoprecipitation (ChIP) assay.
ChIP assay was used to determine the RUNX2 binding sites in
RANKL promoter. Immunoprecipitates were made with an antibody
(rabbit) to RUNX2 (lane 4) or rabbit IgG (lane 3) using lysates made
from PC3 cells. DNA from the input (lane 2) and immunoprecipitates
(lanes 3 and 4) was analyzed by RT-PCR using primers specific for
RUNX2 binding sites on RANKL promoter. As expected, a product
size 153 bp was observed in the RT-PCR analysis. The experiment
was repeated twice and obtained similar results. B-D: The
conditioned media (CM) from PC3 cells untreated (B) or treated with
scrambled (C) and SiRNA (D) to RUNX2 were used for osteoclast
differentiation in vitro. TRAP-positive osteoclasts are stained in dark
purple. Cells were observed under an inverted phase contrast
microscope and images were captured (X 200). The results shown
are representative of three experiments.
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support osteoclastogenesis and osteolysis.
CD44 knockdown reduces RANKL expression and
osteoclast differentiation
Our previous observation demonstrated an underlying
correlation between osteopontin/CD44 signaling and
RANKL expression [28]. CD44 increases RANKL expres-
sion in bone marrow stromal cells (BMSCs). BMSCs iso-
lated from CD44 knockout mice express less RANKL
[47]. Therefore, we sought to determine in PC3 cells, the
possible regulatory mechanisms involved in the activation
of RUNX2 and the role of CD44 signaling in this process.
CD44 is highly expressed in PC3 cells
At first, we evaluated the expression levels of CD44 in
control cells (HPR1 and BPH) and prostate cancer cells
derived from bone (PC3), lymph node (LNCaP) and brain
(DU145) metastases (Figure 3A). Expression of CD44 was
observed in the following order in the cell lines tested:PC3 >DU145 >BPH=HPR1 (Figure 3A). The blot shown
in Figure 3A was exposed for >5 min in order to observe
the expression levels of CD44 in LNCaP, BPH and HPR-1
cells. Expression of CD44 was very negligible in BPH and
HPR-1 cells. As shown by others, CD44 was not observed
in LNCaP cells (Figure 3A) [40,48,49].
Generation of stable CD44 knockdown PC3 cells
In order to determine the role of CD44 in the expression
of RANKL, we have generated PC3 cells knockdown of
CD44. Four constructs were made to knockdown CD44
as described in the Methods section. A significant de-
crease in the expression levels of CD44 was observed in
PC3 cells transfected with silencing CD44 ShRNA con-
structs corresponding to nucleotide sequences 492 bp
and 801 bp (Figure 3C). We have generated about 15–20
individual clones and tested for the expression of CD44.
The expression levels of standard CD44 in the clonal iso-
lates of 801 (lanes 1–3) and 492 (lanes 4 and 5) ShRNA
constructs are shown (Figure 3C). Among the individual
clones tested, one clonal isolate which demonstrated
maximum knockdown of CD44 from 801 and 492 group
(Figure 3C, lanes 1 and 5) was propagated for further
studies shown below. Additionally, immunoblot analyses
show that these cells are negative for CD44 variant iso-
forms (data not shown). Non-silencing scrambled
ShRNA (Sc) construct and vector DNA (V) transfected
cells were used as controls.
RANKL expression and osteoclast differentiation is reduced
in PC3 cells knockdown of CD44
We subsequently evaluated the total cellular (Figure 4A)
and secreted (Figure 4C) levels of RANKL in CD44
knockdown clones and control cells. Secreted levels of
RANKL in CM (Figure 4C, lane 3) and the effect of CM
on osteoclast differentiation (Figure 4G) were shown
with studies carried with a clonal isolate derived from
the 801 bp construct. A significant decrease in the cellu-
lar (Figure 4A, lanes 2 and 3) and secreted levels
(Figure 4C, lanes 3) of RANKL was observed in CD44
knockdown cells (PC3/Sh (801)) as compared with con-
trol cells (A, lanes 1 and 4; C, lanes 1 and 2).
CM from PC3/ShCD44 (801) cells failed to support
differentiation of mouse bone marrow cells into multi-
nucleated osteoclasts (Figure 4G). Multinucleated giant
osteoclasts were observed in bone marrow cultures
added with CM media from control PC3 cells (Figure 4E
and F). Overall, these results implicate CD44 signaling
as an important mediator of RANKL expression.
CD44 signaling regulates RUNX2 expression
CD44-mediated signaling appears to have a role in the
expression of RUNX2 because a neutralizing antibody to
CD44 attenuated RUNX2 expression in chondrocytes
Figure 3 Characterization of stable CD44 knockdown cell lines. A. Western blot analysis: Equal amount of protein lysates (50 μg) made from
indicated cell lines were immunoblotted with a CD44 antibody to detect total cellular levels of CD44 protein. C. Immunoblotting analysis of the
total cellular levels of CD44 in the stable clonal isolates derived from PC3 cells transfected with CD44 ShRNA constructs (801 and 492; lanes 1–5)
is shown. PC3 cells transfected with vector DNA (V) and scrambled ShRNA construct (Sc) were used as controls. B and D: Equal loading of protein
was verified with the GAPDH level in each lane. The experiment was carried out three times with similar results.
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between CD44 receptor and RUNX2 expression in indi-
cated PC3 cell lines by real-time PCR (Figure 5A) and
Western blot (Figure 5B) analyses. Knockdown of CD44
in PC3 cells reduces the expression of RUNX2 at mRNA
(Figure 5A; sh801) and protein levels (B, Sh492 and 801)
as compared to indicated control cells.
Previous studies have shown that phosphorylation of
RUNX2 occurred mostly on the serine residues with a
small amount at threonine and tyrosine residues [19,50].
Therefore, we determined the serine phosphorylation
status of RUNX2 (Figure 5E) in PC3 cells. RUNX2
immunoprecipitates from total cellular (T) and nuclear
(N) lysates were used for immunoblotting with an anti-
body to RUNX2 (D) and phospho-Serine (p-Serine; E).
Phosphorylation of RUNX2 corresponds with the pro-
tein level present in the whole cell and nuclear lysates.Figure 4 Analysis of RANKL expression level in PC3 cells knockdown
protein; A) and conditioned media (CM-20 μg protein; C) were immunoblo
detect the secreted RANKL protein. B and D. The blot in A was stripped an
observed (B). The loading control for the CM was shown by the use of Coo
on osteoclast differentiation in vitro is shown. TRAP-positive osteoclasts are
phase contrast microscope. The results shown are representative of three iReduced phosphorylation corresponds with the low
levels of RUNX2 in whole cell lysates (D and E, lane 1)
and the opposite is true for the nuclear lysates (lane 2 in
D and E). This result is in agreement with the nuclear
localization of RUNX2 in immunostaining analysis
(Figure 1G).
p-Smad 5 localizes in the nuclear region
Several lines of evidence suggest that RUNX2 functions
synergistically with a family of Smad proteins to induce
osteogenesis and modulate tumor growth and metastasis
[51].Therefore, we proceeded to determine whether
Smad protein(s) have any synergistic role with RUNX2.
First, we analyzed the expression and phosphorylation
levels of Smad 2, 3, 5 and 6 in total PC-3 cellular lysates.
Our analyses indeed have shown the presence of Smad
2, 3 and Smad 5 proteins and not Smad 6 in PC3 cells.of CD44. A and C. Equal amount of total cellular lysates (50 μg
tted with a RANKL antibody to detect RANKL protein. CM was used to
d reprobed with a GAPDH antibody. Equal level of GAPDH protein was
massie blue staining of a gel ran in parallel (D). E-G. The effect of CM
stained in dark purple. Images were captured (X 200) with an inverted
ndependent experiments.
Figure 5 Effects of CD44 knockdown on RUNX2 expression (mRNA and protein) and distribution in PC3 cells. A. The expression levels of
RUNX2 mRNA was determined by real-time PCR analysis and normalized relative to GAPDH expression. Bar represents the mean ± SEM of three
different experiments. *p <0.01 vs. untransfected (−) and transfected PC3 cells with scrambled ShRNA construct (Sc) and vector DNA (V). B and C.
Equal amount of lysates (20 μg protein) made from PC3 cells untransfected (−) and transfected with scramble (Sc) and ShRNA CD44 constructs
(492 and 801) were used for immunoblotting analysis with an antibody to RUNX2. Immunoblotting with an antibody to GAPDH (C) was used as a
loading control. D and E. PC3 cells were analyzed for the phosphorylation of RUNX2 in total cellular (T) and nuclear (N) lysates by
immunoblotting of RUNX2 immunoprecipitates with antibodies to RUNX2 (D) and phospho-serine (E; p-Serine). The results shown are
representative of three independent experiments.
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Smad 5 was significantly higher than in Smad 2 and 3
(see Additional file 2: Figure S2). Therefore, we decided
to focus our attention on the role of Smad 5 in RUNX2
function.
We first investigated the nuclear (N, 100 μg), cytoplas-
mic (C, 100 μg) and total cellular (T, 200 μg) levels of
Smad 5 (Figure 6 A) and phospho-Smad 5 (p-Smad 5; B)
by immunoblotting analyses. Smad 5 was observedFigure 6 Analysis of Smad 5 phosphorylation in PC3 cells. A and B; F-
Western blot analysis in nuclear (N), cytosolic (C) and total cellular (T) prote
CD44 (F-H). 50 μg of indicated protein (A-D, F-H) was used for immunoblo
successively with p-Smad 5, GAPDH and histone antibodies (B-D). Similarly,
GAPDH and histone antibodies (G and H). Immunoblotting with an antibod
for normalization of cellular and nuclear protein, respectively. E. Confocal a
(red) antibodies is shown. Distribution of both Smad 5 and p-Smad 5 is sho
representative of three independent experiments.predominantly in total cellular (T) and cytosolic (C)
lysates (Figure 6A, lanes 2 and 3). However, a signifi-
cantly lower level of p-Smad 5 was observed in the cyto-
solic protein (Figure 6B, lane 2). In contrast, equal levels
of phosphorylation of Smad 5 was detected in total cel-
lular and nuclear (N) lysates (Figure 6B, lanes 1 and 3)
although significantly lower level of Smad 5 was present
in the nuclear lysates (A, lane 1). It is possible that the
p-Smad 5 recognized in the total cellular lysateH. Protein and phosphorylation levels of Smad 5 were determined by
ins isolated from PC3 cells (A and B) and PC3 cells knockdown of
tting (IB) analyses. The blot in A was stripped and reprobed
the blot in F was stripped and reprobed twice simultaneously with
y to GAPDH (C and G) and histone (D and H) was used as a control
nalysis of immunostained PC3 cells with Smad 5 (green) and p-Smad 5
wn in the overlay panel. Scale bar-50 μm. The results shown are
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nucleus (6B, lane 1).
Immunostaining and confocal microscopy analyses
(Figure 6E) corroborated the immunoblotting analysis.
Strong Smad 5 staining was observed at the perinuclear
region (indicated by arrows in the green panel) with a dif-
fuse distribution in the nuclei. Distribution in the peri-
nuclear region includes the nuclear membrane. Also,
Smad 5 was present in the cytoplasm and plasma mem-
brane, but to a lesser extent (Figure 6E; green panel).
However, localization of p-Smad 5 was observed largely in
the nucleus (Figure 6E, red). Perinuclear distribution of
Smad 5 may support the phosphorylation event and im-
mediate export into the nuclei at the time of transcription.
Phosphorylation of Smad 5 occurs independent of CD44
signaling
To determine the role of CD44 signaling in the phos-
phorylation of Smad 5, we used the stable PC3/ShCD44
(801) cell line. Phosphorylation of Smad 5 remained the
same in total cellular (T) and nuclear (N) protein of
PC3 cells untransfected (Figure 6F, lanes 1 and 2) orFigure 7 The effect of PKC and integrin αv inhibitor on the phosphor
of interaction of p-Smad 5 with RUNX2. Equal amount of total cellular and
and immunoblotted with a p-Smad 5 antibody (A, top panel). Subsequentl
and p-Serine (bottom panel) antibody after stripping. B. Effect of SiRNA to
SiRNA (Si) nucleotides on Smad 5 levels at 48 and 72 h is shown. Equal am
antibodies to Smad 5, RUNX2 and nucleoporin after stripping. Scrambled R
Effects of PKC and integrin αv inhibitors (lanes 2 and 3) on the phosphoryl
cellular (T) lysate proteins were immunoblotted with a p-Smad 5 antibody.
nuclear localization of RUNX2. Untreated (-) PC3 cells were used as control.
antibody. B-D: Loading control antibodies to GAPDH (C) and nucleoporin (
proteins loaded in each lane. The results shown are representative of threetransfected with scrambled ShRNA (Figure 6F, lanes 4, 5)
and ShRNA (lanes 7 and 8) constructs to CD44. Consist-
ently, phosphorylation is significantly lower in the cyto-
solic protein (lanes 3, 6, and 9) than total cellular (T) and
nuclear (N) proteins (Figure 6F). Knockdown of CD44
signaling had no effects on the expression, phosphoryl-
ation or nuclear localization of Smad 5 protein (Figure 6F,
lanes 7–9). These findings clearly indicate that CD44 sig-
naling appears to have no role in the phosphorylation of
Smad 5.
Phosphorylation of Smad 5 regulates nuclear localization
of RUNX2
Cooperation between RUNX2 and Smads appears to be
structurally coupled [24] and this seems to be important
in eliciting biological signals that regulate the expression
of osteoblast specific genes [26]. Therefore, we assessed
in PC3 cells whether RUNX2 and Smad 5 were structur-
ally linked. We used total cellular (T; 100 μg) and nuclear
(N; 50 μg) lysates for immunoprecipitation with a RUNX2
antibody (Figure 7A). Immunoblotting was performed
with a p-Smad 5 antibody. We show here co-precipitationylation of Smad 5 and RUNX2 localization in the nuclei. A. Analysis
nuclear proteins were immunoprecipitated with a RUNX2 antibody
y, the blot was reprobed sequentially with a RUNX2 (middle panel)
Smad 5 on the nuclear levels of RUNX2. Time-dependent effect of
ount of nuclear proteins were immunoblotted sequentially with
NAi nucleotide (Sc) transfected cells were used as controls (lane 1). C.
ation of Smad 5. Untreated (-) PC3 cells were used as control. Total
D. Effects of PKC and integrin αv inhibitors (lanes 2 and 3) on the
Nuclear lysate proteins (N) were immunoblotted with a RUNX2
B and D) were used to estimate relative amounts of total and nuclear
independent experiments.
Figure 8 The effect of integrin αv inhibitor on RANKL
expression and osteoclast differentiation. A-C: Western blot
analysis. Equal amount of total cellular lysates (50 μg protein; A,
lanes 1 and 2) and conditioned media (CM-20 μg protein; lanes 3
and 4) were immunoblotted with a RANKL antibody. CM was used
to detect the secreted levels of RANKL. The blot in A was reprobed
with a GAPDH antibody after stripping (B). GAPDH level was used as
a control for loading. The loading control for the CM is shown by
the use of Coomassie blue staining of a gel ran in parallel (C). D and
E. The effect of CM on osteoclast differentiation in vitro is shown.
TRAP-positive osteoclasts are stained in dark purple. Images were
captured (X 200) with an inverted phase contrast microscope. The
results shown are representative of three independent experiments.
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lysates (A). However, the levels of immunoprecipitated
p-Smad 5 (top panel) and co-immunoprecipitated RUNX2
(bottom panel) were higher in nuclear lysates (A, lane 2).
As shown in Figure 5, RUNX2 present in the nucleus is
phosphorylated on serine residues (Figure 7A; bottom
panel). This suggests that the formation of a RUNX2-
p-Smad 5 complex takes place in the nucleus and the
complex is phosphorylated.
Next we utilized RNA intereference to examine the
effects of Smad5 knockdown in the nuclear localization
of RUNX2. As shown in Figure 7B, Smad 5 level was
reduced in a time-dependent manner at 48 h and 72 h
(B-top panel, lanes 2 and 3) so did nuclear levels of
RUNX2 (middle panel, lanes 2 and 3). These results in-
dicate that RUNX2 nuclear localization of RUNX2 seems
to be highly dependent on Smad 5 function.
Alpha v beta 3-PKC dependent pathway regulates the
phosphorylation of Smad 5
In an attempt to delineate the possible signaling pathway
involved in the phosphorylation of Smad 5, PC3 cells
were treated with a conventional PKC inhibitor
(Gö6976; 100nM) and an inhibitor to αv (cyclic RGD;
100nM) for 16 h at 370C as described previously [52].
Immunoblotting analysis of total cellular lysates (T,
100 μg) with an antibody to p-Smad 5 was performed.
Our data show that these inhibitors blocked the phos-
phorylation of Smad 5 to a significant level (Figure 7C,
lanes 2 and 3). Untreated PC3 cells were used as con-
trols (lane 1). These data provides evidence that αvβ3
signaling regulates the phosphorylation of Smad 5, in-
cluding PKC as an important signaling molecule within
the αvβ3 signaling pathway.
We next asked whether inhibition of Smad 5 phos-
phorylation reduces the localization of RUNX2 in the
nuclei (Figure 7D). We examined RUNX2 levels in the
nuclear lysates (N, 50μg) made from PC3 cells treated
with a αv and PKC inhibitor (lanes 2 and 3). A decrease
in the levels of RUNX2 in cells treated with inhibitors
(lanes 2 and 3) corresponds with the decrease in the
phosphorylation of Smad 5 (Figure 7C, lanes 2 and 3).
Following these interesting and novel findings, we sug-
gest that phosphorylation of Smad 5 is an indispensable
step for RUNX2 function.
Alpha v beta 3-dependent pathway regulates the
expression of RANKL
We next examined whether inhibition of αv signaling
reduces RANKL levels in PC3 cells (Figure 8A) and
osteoclast differentiation in vitro (D and E). A decrease
in the cellular (Figure 8A, lane 1) and secreted (lane 3)
levels of RANKL was observed in PC3 cells treated with
an inhibitor to αv (indicated +; Figure 8). Conditionedmedia from PC3 cells treated with a αv inhibitor failed
to support differentiation of mouse bone marrow cells
into multinucleated osteoclasts in vitro (Figure 8E). Mul-
tinucleated giant osteoclasts were observed in bone mar-
row cultures treated with CM media from control PC3
cells (Figure 8D). Taken together, our results indicate
that the formation of the nuclear RUNX2/p-Smad 5
complex is a critical mechanism within metastatic pros-
tate cancer cells to facilitate the expression of RANKL.
Phosphorylation of RUNX2 and Smad 5 as well as RANKL
expression are significantly increased in human prostate
cancer
Immunoblotting analyses of total cellular and membrane
protein isolated from human tissues derived from normal
prostate (NT) and prostate tumor (TT) were performed
with an antibody to RANKL (Figure 9). Expression of
RANKL was observed in the total cellular and membrane
fractions of the lysate protein from TT (Figure 9A and B,
lane 2). RANKL protein was below the level of detection
in normal tissue lysates (Figure 9A and B, lane 1).
Next, immunoblotting analyses were performed in
the nuclear fractions of NT and TT with antibodies to
RUNX2, p-Serine, p-Smad 5 and Smad 5 proteins
(Figure 9). While the protein levels remain the same in
NT and TT (Figure 9E, lanes 1 and 2), phosphorylation
of RUNX2 was markedly increased in the nuclear frac-
tion of TT than NT (Figure 9F, lanes 1 and 2). On the
other hand, levels of Smad 5 and p-Smad 5 were elevated
Figure 9 Western analyses in prostatic normal and tumor
lysates. Total cellular (A and C), membrane (B and D) and nuclear
(E to I) lysates from normal (NT) and prostatic tumor (TT) tissue
(~20 μg protein) were immunoblotted (IB) with a RANKL (A and B),
RUNX2 (E), phosphoserine (p-Serine; F), phospho-Smad 5 (p-Smad 5;
G) and Smad 5 (H) antibody. Equal loading of the protein was
shown in total cellular, membrane and nuclear lysates by relevant
immunoblotting analysis with antibodies to GAPDH (C), actin (D)
and nucleoporin (I). The results shown are representative of three
independent experiments with three different lysates purchased
from the vendor.
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and H; lane 2) as compared with NT (G and H, lane 1).
RANKL expression is markedly elevated in human
prostatic adenocarcinoma tissues
To further validate the immunoblotting findings, we car-
ried out immunohistochemistry analyses with antibodies
to RANKL, RUNX2, Smad 5 and p-Smad 5 in a human
prostate cancer tissue microarray (TMA). The specific tis-
sue microarray used in this study contained 6 cases of
prostatic adenocarcinoma with 6 adjacent normal tissues.
Relative distribution of indicated proteins in immunos-
tained TMA sections were semi-quantitatively analyzedTable 1 Expression of RANKL, RUNX2, Smad 5 and p-Smad 5
sections
Grade Cells RUNX2 S
Normal prostatic epithelial
cells and PCa adjacent to
these cells (n = 26)
Cancer cells
appear normal
Normal cells = 63.0 ± 8% N
PCa= 28% P
Stromal cells <5% S
Adenocarcinoma Grade 1




PCa = 60.7 ± 23% P
Stromal cells = <5% S





PCa = 71.3 ± 20% P
Stromal cells ~5-8% S
Adenocarcinoma





PCa = 76± 8% P
Prostatic carcinoma and normal tissue microarray containing 12 cases/24 cores was
performed with antibody to RANKL, RUNX2, Smad 5 and phospho-Smad 5 (p-Smadby two other investigators and provided in Table 1. Sec-
tions shown in A, C, E and G have normal, hyperplastic
and mildly dysplastic prostate tissue. Sections in B, D, F
and H contain either moderately or poorly differentiated
prostatic adenocarcinoma at grade 2 and 3. Hyperplastic,
moderately differentiated prostatic tumor tissue contains
luminal or basal epithelial cells. Moderately differentiated
prostatic adenocarcinoma cells filling luminal space are
indicted by arrows in the sections containing normal
and hyperplastic prostate tissue (Figure 10, sections A’
and C’). High magnification regions shown below each
of the cores is indicated by a corresponding rectangular
field in top panels (A-H). Immunohistochemistry ana-
lyses (Figure 10) confirmed the observations shown in
Figure 9 in the following aspects: a) RANKL expression
increases in prostate cancer tissue (Figure 10B) as com-
pared with normal tissue (Figure 10A). RANKL expres-
sion is higher in prostatic cancer tissue (indicated by an
arrow in A’) adjacent to normal tissue (indicated by an
asterisk in A’); b) Diffuse cytoplasmic and intense nu-
clear distribution of RUNX2 was observed in both nor-
mal and prostate cancer tissue sections (C, D, C’ and
D’). The unavailability of the phospho-RUNX2 antibody
prevented us from determining its localization in the
normal and tumor prostatic tissue. However, based on
immunoblotting analyses in PC3 nuclear lysates and
human prostate cancer cells, we propose that RUNX2
localized in the nucleus of cancer tissue is mostly phos-
phorylated (Figure 7F, lane 2); c) Diffuse distribution of
Smad-5 was observed in normal and prostate carcinoma
sections. Distribution of Smad 5 is elevated in carcin-
oma tissues (F) as compared with normal tissue sections
(E). Smad 5 staining was mostly cytoplasmic (E, F, E’
and F’). Phospho-Smad 5 (p-Smad 5) staining is very
sparse in normal prostatic epithelial cells (G and G’) but
predominates in sections containing adenocarcinomain prostatic carcinoma and normal tissue microarray
mad 5 p-Smad 5 RANKL
ormal cells = 18.3 ± 6% Normal cells = <6% Normal cells = 22 ± 6.5%
Ca= 33% PCa= 16 ± 6% PCa =12 ± 3.1%
tromal cells 8-10% Stromal cells = <6%
Ca= 56.4 ± 8%** PCa= 32 ± 5%** PCa = 42± 8.4%**
tromal cells =8% Stromal cells = <5% Stromal cells =12 ± 2.82%
Ca >63.3 ± 12%** PCa >59 ± 14%** PCa >46 ± 6.2%**
tromal cells ~5% Stromal cells ~5% Stromal cells =10 ± 3.2%
Ca >72± 11%** PCa >78 ± 18%*** PCa = 65± 13%**
used. Stainings were repeated two times. Immunohistochemistry was
5). **p <0.01 and ***p <0.001 staining intensity vs. normal cells.
Figure 10 Immunohistochemistry on TMA derived from normal and cancerous prostate tissue. Immunohistochemical staining was
performed in prostate cancer and normal tissue microarray with an antibody to RANKL (A and B), RUNX2 (C and D), Smad 5 (E and F) and p-
Smad 5 (G-H). Normal tissue adjacent to prostate cancer are shown in A, C, E and G. Prostate carcinoma at grade 2–3 are shown in B, D, F and H.
Arrows in C’, D’ G’ and H’ point to nuclear localization of RUNX2 and p-Smad-5 proteins. An arrow in A’ points to a prostate carcinoma filled
lumen (A’) adjacent to normal tissue (indicated by an asterisk; A’). Sections were immunostained (brown) with indicated primary antibody as
described in the Methods section. Immunostained sections were counterstained with hematoxylin stain (blue). Magnification is 50X in A-H.
Location of the high magnification (X200) regions shown in A’-H’ is indicated by a rectangle field in A-H. Staining was repeated two times.
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in the nuclei (indicated by arrows in G’ and H’).
Discussion
Expression of CD44 (standard or variant isoforms) has
been considered a prognostic marker for the progression
of prostate cancer. The mechanism by which CD44 reg-
ulates the progression of prostate cancer is largely un-
known. The present study was performed to evaluate
the role of CD44 in prostate cancer-induced bone me-
tastasis. We screened three cell lines (PC3, DU145, and
LNCaP) for the expression of CD44. Normal prostatic
epithelial (HPR-1) and benign prostatic hyperplasic cells
(BPH) were used as controls. PC3 and DU145 cells were
established from the bone and brain metastatic lesions
of a prostate cancer patient, respectively. Our studies are
in agreement with the majority of earlier studies [53,54]
in the expression of CD44 in androgen independent PC3
and DU145 cells, but not in androgen dependent LNCaP
cells, which is established from a lymph node metastasis.
Stable expression of androgen receptor in PC3 cellsreduces CD44 expression to a significant level (data not
shown).
The present study was undertaken to determine the
possible mechanisms involved in the formation of osteo-
lytic lesions associated with metastasis of prostate cancer
cells to bone and the significance of CD44 and αvβ3 sig-
naling. Previous studies in CD44 knockout mice link
CD44 receptor with RANKL expression [47]. Our results
in PC3 cells show that RANKL expression is in part
mediated by CD44 signaling through RUNX2. As a re-
sult of CD44 expression, we have found expression of
RANKL and MMP9 through RUNX2-dependent signal-
ing in PC3 cells. RUNX2 SiRNA reduces MMP9 expres-
sion but not MMP2 at mRNA level. On the other hand,
androgen-dependent LNCaP cells demonstrated expres-
sion and secretion of MMP2 as a major metalloproteases
(Additional file 1: Figure S1). MMP2 expression may
occur independent of RUNX2 and CD44 signaling in
LNCaP cells. Consistent with our studies, others have
shown negligible Runx2 in normal prostate epithelial
and non-metastatic LNCaP cells. High Runx2 levels are
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expression of metastasis-related genes (MMP9, MMP13,
VEGF, osteopontin) and secreted bone-resorbing factors
(PTHrP, IL8) promoting osteolytic disease. Moreover, it
was identified in co-culture studies that PC3 cells pro-
mote osteoclastogenesis and RUNX2 has a role in it
[18]. This suggests a role for RUNX2 in the expression
of RANKL.
RUNX proteins are expressed in prostate tissue and
prostate cancer cells [18,55,56]. Breast and prostate can-
cers over expressing RUNX2 metastasized predominantly
to bone [16,20]. We have shown a direct relationship of
CD44 expression with RUNX2 activation in androgen-
independent PC3 cells. Knockdown of CD44 reduced the
expression of RUNX2 at mRNA and protein levels and
hence reduced RUNX2-mediated signaling. Our studies
demonstrate the possible role of CD44 signaling in
RUNX2-mediated expression of RANKL. One possible
explanation for RUNX2-regulated RANKL expression in
PC3 cells may be associated with the lack of androgen re-
ceptor signaling. Androgen receptor was shown to bind
RUNX2 and abrogates its binding to DNA and possibly
to other nuclear DNAs [14]. It appears that CD44 expres-
sion in androgen-independent cells (e.g. PC3 cells) coun-
teracts androgen receptor effects in terms of activation of
RUNX2- mediated events. Therefore, knockdown of
CD44 signaling in PC3 cells has the potential to reduce
RUNX2 mediated signaling.
Hyaluronan (HA), the major non-protein glycosamino-
glycan component of the extracellular matrix in mamma-
lian bone marrow, functions in part through its receptor,
CD44, to stimulate a series of intracellular signaling
events that lead to RANKL expression [47]. We have
shown previously that osteopontin (OPN) is secreted by
PC3 cells. Over-expression of OPN in PC3 cells increases
the secretion of RANKL through αvβ3 signaling [28]. Our
current mechanistic evaluation studies in PC3 cells sug-
gest a role for CD44 signaling in the phosphorylation of a
RUNX2 and integrin αvβ3 signaling in the phosphoryl-
ation of Smad-5 independent of CD44 signaling. How-
ever, further studies are required to understand the
precise contribution of downstream kinase(s) to the regu-
lation of RUNX2 phosphorylation.
Runx2 nuclear localization was found to be up-
regulated in prostate cancer and was suggested that this
could be used as a predictor of metastasis in prostate
cancer [57]. Several studies have shown that RUNX2
regulates localization of activated Smads in the sub-
nuclear loci [24,58,59]. RUNX2 cooperates with Smads
to induce differentiation of osteoblasts [26,60] and ex-
pression of collagenase in breast cancer cells [61].
RUNX2 forms complexes with Smad proteins as a re-
quirement for mediating BMP/TGF β responsiveness in
tumor cells. These effects contribute to tumor growth inbone and the accompanying bone loss in metastatic
breast cancer cells [20]. Formation of the Runx2/Smad
transcriptional complex is dependent on the phosphoryl-
ation state of these proteins [58]. Likewise, we detected
predominant localization of phosphorylated RUNX2 and
Smad 5 in the nuclei of lysates made from PC3 cells,
prostatic adenocarcinoma and in tissue microarray sec-
tions containing primary prostatic tumor (grade 2–4).
Distinct relationship has been shown to exist between
each Smad and RUNX2, [26,27,58,62,63]. Not only Smad
5 but also Smads 2 and 3 were shown to physically inter-
act with RUNX2 in P19 embryonic carcinoma cells [23].
RUNX2/Smad 3 interaction stimulated collagen 3 expres-
sion in breast cancer cells [61]. Runx2/Smad3 complex
negatively regulated endogenous and TGF-beta-induced
connective tissue growth factor gene expression in vascu-
lar smooth muscle cells [64]. We have found that PC3
cells express Smad −2, -3 and −5 (Additional file 2: Figure
S2). Smad 5 interaction was more with RUNX2 and this
interaction regulates the expression of RANKL in prostate
cancer cells.
RUNX2/Smad complex was shown to regulate the ex-
pression of RANKL in osteoblasts [24]. Although various
studies have addressed the role of RUNX2 and Smad(s) in
the regulation of expression of RANKL, the mechanisms
underlying this process have remained largely unknown.
Also the role of Smad5 in the expression of RANKL
needs further elucidation. The data presented here show
that Smad 5 and RUNX2 are co-immunoprecipitated in
the nuclear fraction. RUNX2/Smad 5 complex regulates
the expression of RANKL in PC3 cells. Interaction of
RUNX2 with RANKL promoter was observed with CHIP
assay. Binding of RUNX2 to the ctggaaccactggagt motif
site on the RANKL is shown by CHIP assay. Although
knockdown of RUNX2 or inhibition of phosphorylation
of Smad-5 by an inhibitor to αv reduces the levels of
RANKL, direct binding of Smad 5 with RANKL promoter
was not observed. Future studies should delineate the
relevant interactions between these proteins.
Interestingly, we have also observed reduced levels of
RUNX2 and RANKL expression in cells treated with an
inhibitor to αv or SiRNA to Smad5. These results indi-
cate that RUNX2 is a major target gene of CD44 and
Smad 5 signaling pathway. This is consistence with
observations shown by others that Smad 5 is an up-
stream regulator of RUNX2 [26,51,60]. Over expression
of Smad 5 increases RUNX2 levels in human MG63
osteosarcoma cells [51]. RUNX2 expression is transiently
up regulated by TGF-β and BMP-2 activated Smads in
mesenchymal precursor cell differentiation [26,60]. Smad
2 and 3 are expressed in PC3 cells; however, these pro-
teins could not compensate the function of Smad 5.
Therefore, it is possible that, a) Smad 5 which induces
RUNX2 expression might also be translocated to
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with RUNX2 may not occur for RANKL expression in
response to integrin αvβ3 signaling. BMP2 signaling
contributes to the high level of Runx2-Smad interaction
which activates RANKL in osteoblasts. CD44/Smad sig-
naling pathway has been shown to have a regulatory role
in osteoblast differentiation in the absence of BMPs [65].
The underlying molecular mechanism by which αvβ3-
activated Smad 5 regulates RUNX2 expression needs
further elucidation. Taken together, bone metastatic
prostate cancer cells (PC3) are osteomimetic and are
expressing genes and proteins as observed in osteoblasts.
However, the expression of osteoblastic specific genes in
metastatic cancer cells does not necessarily involve the
same pathway as observed in osteoblasts.
Conclusions
Runx2 regulates early metastatic events in breast and
prostate cancers, tumor growth, and osteolytic bone dis-
ease. Runx2 forms co-regulatory complexes with Smads
in subnuclear domains to regulate gene transcription.
Consideration is given to the potential for inhibition of
this transcription factor as a therapeutic strategy up-
stream of the regulatory events contributing to the com-
plexity of metastasis to bone. BMP/TGF-β and other
growth factor signaling pathways regulate the formation
of RUNX2/Smad complexes which in turn contribute to
tumor growth in bone and the accompanying osteolytic
disease (rev in [20]. As reported by others [58], we have
also shown that RUNX2 and Smad 5 form a complex in
the nuclei of PC3 cells and that both Smad5 and RUNX2
in nuclei are phosphorylated to form a transcriptional
complex. Indeed, signaling by integrin αvβ3 and CD44
plays a role in the phosphorylation of Smad 5 and
RUNX2, respectively. We have presented evidence that
integration of two different signaling pathways (CD44
and αvβ3) facilitate osteoclastogenesis and bone loss via
a RUNX2/Smad5/RANKL axis in metastatic prostate
cancer cells. Crosstalk between integrin αvβ3 and CD44
signaling pathway assists in the phosphorylation of Smad
5 and RUNX2, respectively. Further study will be
required for comprehensive understanding of the down-
stream signaling molecules involved in the phosphoryl-
ation of RUNX2 and Smad 5 and the details of sequence
specific interaction between these proteins.
Materials and methods
Materials
Antibodies to RANKL, RUNX2, Histone and GAPDH as
well as HRP-conjugated secondary antibodies (rabbit,
goat and mice) were purchased from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA). Antibodies to CD44
and sampler kit containing antibodies to Smads (phos-
pho (P) -Smad1/5, P-Smad2, Smad2, Smad4, Smad 5 andSmad6) were purchased from Cell Signaling Technologies
(Danvers, MA). Macrophage colony-stimulating factor-1
(MCSF-1) was purchased from R&D Systems (Minneap-
olis, MN). Cy2- and Cy3-conjugated secondary antibodies
were purchased from Jackson Immunoresearch Labora-
tory, Inc. (West Grove, PA). An inhibitor to PKC
(Gö6976) was purchased from Calbiochem (La Jolla, CA).
A αv inhibitor (Cyclic RGD peptide) was purchased from
Peptides International (Louisville, Kentucky). Complete
mini protease inhibitor tablet was purchased from Roche
Applied Science (Indianapolis, IN). Protein estimation re-
agent kit, molecular weight standards for proteins, and
polyacrylamide solutions were purchased from Bio-Rad
(Hercules, CA). Polyvinyldifluoride (PVDF) membrane
for immunoblotting analysis and Amicon centrifugal con-
centrator devices for concentrating the protein in the
conditioned media were obtained from Millipore Corp.
(Bedford, MA). ECL reagent was purchased from Pierce
(Rockford, IL). Vector Stain Elite and avidin-biotin com-
plex (ABC) kit for immunohistochemistry were bought
from Vector Laboratories (Burlingame, CA). Human
prostate tumor and normal tissue lysates (total tissue,
membrane and nuclear lysates) were purchased from
Abcam (Cambridge, MA). TMAs containing 12 (24 cores)
24 (48 cores) and 40 (96 cores) cases were bought from
US Biomax, Inc.Generation of PC3 cells knockdown of CD44
Four different silencing and one control scramble
ShRNA constructs for the CD44 cDNA sequences (Gen-
bank -NM_000610.3) were made using Shanghai Gene
Pharm Corporation services (Shanghai, China). Target
sequences for each of the silencing and scrambled
ShRNA constructs are as follows:
1) 50GCGCAGATCGATTTGAATATA-30 (shCD44-492)
2) 50GCTCCACCTGAAGAAG ATTGT-30 (shCD44-
801)
3) 50-GCTTC ACCTACTGCAAATCC-30 (shCD44-
1874)
4) 50-GGA AGAAGATAAAGACCATCC-30 (shCD44-
1994)
5) Scrambled ShRNA 50-
GCATGTAGCGTTCGTAAATAA-30 (shCD44-
scramble). Constructs were generated in pGPU6/
GFP/Neo-vector. PC3 cells were transfected with
these constructs and vector DNA using
lipofectamine 2000 according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). Cells were
cultured in Roswell Park Memorial Institute-1640
(RPMI 1640) media containing 10% FBS. After 24 h
transfection, the cells were selected using G418
sulfate in the same medium. G418 sulfate resistant
cells were analyzed for CD44 levels by
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constructs which gave the best silencing effect of
CD44 in PC3 cells were used for the isolation of
individual clones. A significant decrease in the levels
of CD44 was observed with shCD44-492 and −801
constructs. Individual clones (about 15–25) were
isolated for each construct and cultured in complete
medium containing G418 sulfate (200 μg/ml). About
two to three clones from each construct (492 and
801) demonstrated a considerable decrease in the
levels of CD44. Individual clones from each
construct that exhibited highest levels of reduction
in endogenous CD44 levels were used for the
experiments described here. These cells were
designated as PC3/Si (CD44).
Cell culture
Prostate cancer cells (PC3, PC3 derived cell lines,
LNCaP and DU145) and benign prostatic hyperplasic
cells (BPH-1) were cultured in RPMI 1640 medium con-
taining 5% or 10% fetal bovine serum (FBS) [28,66]. HPR-
1 cells were cultured in keratinocyte medium supplemen-
ted with epidermal growth factor (EGF) (2.5 mg/500 ml)
and bovine pituitary extracts (25 mg/500 ml) (Gibco BRL,
Life Technologies, Bethesda, MD) as described previously
[67]. Media were supplemented with penicillin and
streptomycin (1%) and the cells were maintained at 37°C
in a humidified incubator with 5% CO2.
Quantification of RANKL in the conditioned medium
Cells of interest were grown to 80-90% confluence in
RPMI-1640 medium containing 10% FBS. Cultures were
then switched to serum-free RPMI-1640 medium for
72 h. The harvested CM was concentrated with Amicon
centrifugal filter devices (Millipore Corporation, Bed-
ford, MA). Protein concentrations were measured using
the Bio-Rad protein assay reagent kit. Quantification of
the secreted RANKL in the conditioned media was done
by comparative analysis with different concentrations of
either BSA or purified GST-RANKL using 12% poly-
acrylamide gel containing SDS (SDS-PAGE). Coomassie
staining of the SDS-PAGE and immunoblotting with a
RANKL antibody were performed to determine the con-
centration of RANKL in the medium [28].
Preparation of osteoclast precursors
Mouse osteoclasts were generated in vitro using mouse
bone marrow cells as described previously [68]. Cells iso-
lated from five mice were cultured into 100-mm dishes
with 20 ml of α-MEM medium supplemented with 10%
fetal bovine serum (α-10). After culturing for 24 h, non-
adhered cells were layered on histopaque-1077 (Sigma)
and centrifuged at 300×g for 15 min at room temperature.
The cell layer between the histopaque and the media wasremoved and washed with α–10 medium at 2000 rpm for
7 min at room temperature. Cells were resuspended in α-
10 media and cultured with the appropriate concentrations
of M-CSF-1 (10 ng/ml) and RANKL (55–75 ng/ml). In
order to determine the effect of secreted RANKL on osteo-
clast differentiation, mouse bone marrow cells were treated
in the same way with M-CSF-1 but with conditioned
medium (CM; 50-100 μg protein). CM collected from PC3,
PC3-derived cell lines, DU145, LNCaP, BPH, and HPR-1
were used for osteoclast differentiation. After 3 days in cul-
ture, cultures were added with fresh α–10 medium con-
taining M-CSF1 and respective CM. Multinucleated
osteoclasts were observed from day 4 onwards. About 75-
80% TRAP-positive multinucleated giant osteoclasts were
observed from day 5 onwards [69].Treatment of PC3 cells with SiRNA to Smad 5 and
inhibitors and preparation of total cellular lysates
PC3 cells cultured in RPMI-1640 media containing 10%
FBS at 37°C were treated with PKC inhibitor (Go6976;
100nM) or integrin αv inhibitor (cyclic RGD; 100nM)
for 16 h. SiRNA and non-targeting SiRNA control
nucleotides for Smad 5 were purchased from Santa Cruz
biotechnology, Inc. (Catalog No. sc-38378). Transfection
was performed with lipofectamine as described previ-
ously [70]. Scrambled and SiRNA nucleotides were used
to a final concentration of 50 nM for 48 and 72 h. Fol-
lowing various treatments, cells were washed three times
with cold PBS and added with cold RIPA lysis buffer
(10 mM Tris–HCl, pH 7.2, 150 mM NaCl, 1% deoxycho-
late, 1% Triton X-100, and 0.1% SDS) [71]. Lysis buffer
was supplemented with EDTA- free complete mini pro-
tease inhibitor cocktail (1 tablet per 10 ml lysis buffer)
immediately before use. After incubating on ice for
10 min, lysates were centrifuged for 5 min at 6,000 rpm
at 4°C. The supernatants were saved and protein con-
centrations were measured using the Bio-Rad protein
assay reagent kit. Protein lysates were subjected to SDS-
PAGE (8 or 12% gels) and Western blot analysis as
described previously [71].Preparation of cytoplasmic and nuclear protein fractions
Cells were lysed in a lysis buffer containing 10 mM Tris
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM EGTA and
protease inhibitor (1 tablet/10 ml buffer). Lysate was
centrifuged at 500 × g to separate the nuclear pellet from
the supernatant. The supernatant was considered as a
cytosolic fraction. The nuclear pellet was resuspended
by pipetting up and down with a P200 pipette tip in a
buffer containing 20 mM Tris pH 7.5, 25% glycerol,
1.5 mM MgCl2, 400 mM NaCl and 0.5 mM EGTA. The
suspension was centrifuged at 20,000× g for 15 min at 4°C
and the supernatant was used as nuclear fraction. Equal
Gupta et al. Molecular Cancer 2012, 11:66 Page 14 of 17
http://www.molecular-cancer.com/content/11/1/66concentration of lysate proteins were used for Western
blot analysis [71].
Immunostaining
PC3 cells were cultured on cover slips in a 30 mm dish
for overnight at 370C prior to staining. Cells were
washed three times with PBS and fixed in 4% parafor-
maldehyde–PBS for 20 min. After washing three times
with PBS, cells were permeablized with 0.1% Triton X–
PBS for 15 min. Subsequently, cells were blocked and
immunostained with antibodies (1:100 dilution) of inter-
est as described previously [70]. Cells were then washed
and counterstained with respective isotype specific IgG
conjugated with CY2 and CY3 fluorophore for 2-3 h at
40C. The cells were washed and mounted on a slide in a
mounting solution (Vector Laboratories, Inc.). The
immunostained cells were viewed and photographed on
a Bio-Rad confocal laser-scanning microscope. Images
were stored in TIF image format and processed by the
Adobe Photoshop software program (Adobe Systems,
Inc., Mountain View, CA).
RNA extraction and quantitative real-time PCR with
RUNX2
Total RNA from different cell lines was isolated with
TRIzol kit protocol with the DNA digest (Invitrogen,
Carlsbad, CA). Reverse transcription reaction was per-
formed in a 20 μl-reaction volume with 1 μg of total
RNA by following the instructions provided by the
manufacturer (Invitrogen, Carlsbad, CA). The cDNA was
stored at -200C until further use. For real time PCR,
Runx2 primers (forward-50CGGCCCTCCCTGAACTCT30;
reverse- 50TGCCTGCCTGGGGTCTGTA30) were used
[55]. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (forward-50 TGCA CCACCAACTGCTTAG30
and reverse-50GATGCAGGGATGATGTTC30) was used
for normalization. Each reaction was performed in dupli-
cates or triplicates in 25 μl volume in 96-well plates with
a SYBR green reaction mix (Applied Biosystems Group)
in an ABI 7000HT thermocycler (2 min at 50°C, 10 min
at 95°C and 40 cycles of 15 s at 94°C and 1 min at 60°C)
with 600-900nM primers as described previously [72].
The expression was calculated relative to that of control
cells and normalized for GAPDH measured under the
same conditions (Applied Biosystems/Roche, Branch-
burg, NJ), using the 2–ΔΔCT method [73].
Immunohistochemistry
Prostatic adenocarcinoma tissue microarray (TMA) sec-
tions containing 6 cases of prostate adenocarcinoma
with 6 adjacent normal prostate tissues in duplicate
cores per case were purchased from the US Biomax, Inc
(Rockville, MD). TMA sections were processed, stained,
and analyzed essentially as described previously [74].Antigen retrieval was done using a buffer containing
10 mM Tris base pH 9, 1 mM EDTA and 0.05%Tween
20 in a microwave for 20 min. After incubation with 3%
hydrogen peroxide in PBS for 30 min., sections were
washed with PBS and then blocked either in 2.5% BSA
or horse serum in PBS for 1 h at RT. Sections were then
incubated with the primary antibodies diluted in block-
ing solution overnight at 4°C. After washing with PBS,
slides were incubated with biotinylated secondary anti-
bodies (1:400 dilutions) for 1 h, followed by the avidin-
biotin complex (ABC) method using ABC kit (Vector
Laboratories, Burlingame, CA) for 30 min. Slides were
washed and developed in 3,3-diaminobenzidine (DAB)
for 2–3 min. Immunostained sections were counter-
stained with hematoxylin, dehydrated and mounted with
Permount (Fisher Scientific). Immunostained sections
were scanned using an Aperio ScanscopeW CS instru-
ment (Aperio scanscope CS system, Vista, CA). Relative
distribution of interested proteins in immunostained
TMA sections were semi-quantitatively analyzed by two
other investigators as well.
Reverse transcription- polymerase chain reaction (RT-PCR)
analysis
RT-PCR was done as described previously [70]. Total
RNA was isolated and cDNAs were synthesized using
2 μg of total RNA. RT-PCR was done with the following
primers: RUNX2 (406-bp product) - forward, 50
ATTTAGGGCGCATTCCTCATC-30 and reverse, 50-
TGTAATC TGACTCTGTCCTTGTGGAT-30. GAPDH
level was used for normalization. Samples were electro-
phoresed on an agarose gel and stained with ethidium
bromide.
Chromatin immunoprecipitation assay (ChIP) was
performed according to the manufacturer’s guidelines
(Millipore, Cat#-17-295) and as described previously
[75]. Briefly, PC3 cells were fixed by adding formalde-
hyde (Sigma, St. Louis, MO) to the medium to a final
concentration of 1%. After 15 min the cells were
washed, resuspended in CHIP-lysis buffer (Millipore)
and sonicated. Immunoprecipitation was carried out at
40C overnight using anti-RUNX2 (2 μg; rabbit poly-
clonal antibody) or non-immune rabbit IgG as a con-
trol. Immune complexes were washed, eluted and
protein-DNA cross linking was reversed according to
the manufacturer’s protocol. Immunoprecipitated DNA
was quantified by RT-PCR using primer pairs (for-
ward-50 CTGCGTCTTCTTTAACCCATCT30; reverse-
50CCCTCCCTCTCTCTCAAT CTCT30) in the RANKL
promoter with expected product size 153 bp.
Statistical analysis
All experiments were performed in triplicates and
repeated three to four times and values presented as
Gupta et al. Molecular Cancer 2012, 11:66 Page 15 of 17
http://www.molecular-cancer.com/content/11/1/66mean ± SEM. A value of p <0.05 was considered sig-
nificant. Statistical significance was determined by
analysis of variance (ANOVA) with the Bonferonni
corrections (Instat for IBM; Graph pad software; San
Diego, CA).Additional files
Additional file 1: Figure S1. Analysis of the effects of SiRNA to RUNX2
on MMP9 and MMP2 RNA and protein levels (A-E) and revelation of
major MMPs present in PC3 and LNCaP cells (F). A-D: We determined the
effects of RUNX2 knockdown on the expression of MMP9 and MMP2 at
mRNA (Figure S1-A) and protein levels (Figure S1D) in PC3 cells. Dose-
dependent decrease in the levels of RUNX2 expression was observed in
PC3 cells treated with SiRNA to RUNX2 at concentrations of 10, 20, and
50nM. The decrease was maximal (>90%) at 50nM RUNX2 SiRNA (A, lane
4). PC3 cells treated with scrambled RNAi (50nM) were used as control (A,
lane 1). SiRNA to RUNX2 had very negligible effects on the changes in
the levels of mRNA expression of MMP2 in PC3 cells (lane 6). GAPDH was
used as internal control (Figure S1-B). A decrease in the expression of
MMP9 at mRNA (Figure S1-A, lane 4) parallels with the MMP9 activity (~
90kDa) in the conditioned medium isolated from cultures of PC3 cells
treated with RUNX2 SiRNA (Figure S1-E, lane 3). MMP9 activity was
determined by zymogram analysis. About 50μg membrane protein was
used for the gelatin zymography to determine the activities of MMP9
(S1-E). As shown previously [Ref.28], only the active form of MMP-9 was
observed in the conditioned medium (Figure S1-E, lanes 1-3). The activity
of a recombinant MMP-9 protein containing pro- and active band was
used as an identification marker (lane 4 in S1-E). Furthermore, the
decrease in the protein levels of RUNX2 (~55kDa) in SiRNA to RUNX2
treated cells (Figure S1-C, lane 3) corresponds with a decrease in the total
cellular protein levels of MMP 9 (Figure S1-D, lane 3) but not MMP 2
(~72kDa). MMP 2 levels remain the same in control untreated as well as
scrambled RNAi and SiRNA to RUNX2 treated cells (Figure S1- D). These
results imply that the RUNX2 is not a direct binding factor to induce
transcriptional activation of MMP 2.F: Zymogram analysis with normal
prostatic epithelial cells (HPR1) was used as a control (lane 4) for prostate
cancer cells derived from lymph node (LNCaP, lane 2) and bone (PC3,
lane 3) metastases. The activity of a recombinant MMP2 and MMP9
protein containing pro and active bands (indicated by arrows) were used
as an identification marker (lane 1). LNCaP cells demonstrated MMP2 as a
major metalloproteases where as MMP9 was observed as major MMP
although MMP2 was observed at mRNA (Figure 1A) and protein levels
(Figure S1-D and F) in PC3 cells. About 75μg total cellular protein was
used for zymogram analysis as shown previously [ref. 28]. Method:
Gelatin zymography: Conditioned media collected from various PC3 cell
lines were concentrated approximately 10-fold) with a centricon
concentrator (Amicon, Beverly, MA). Ten micrograms of concentrated
media protein in 10-20 μl were mixed with gel loading buffer with no
reducing agent (βME or DTT) and incubated at RT for 10–15 min. SDS-
PAGE containing 0.1% gelatin was used for electrophoresis. Samples were
loaded without heating with sample buffer. After electrophoresis, gels
were incubated overnight in a buffer containing 50 mM Tris-HCl, pH 7.6,
5 mM CaCl2, 1 μM ZnCl2, and 1% Triton X-100. Triton was used to
remove SDS from the gel. Gels were then stained with Coomassie
brilliant blue for 2–3 h and destained with 7% acetic acid or water.
Gelatinolytic activity was detected as clear bands in the background of
blue staining [ref.28].
Additional file 2: Figure S2. Immunoblotting analysis for Smad 2, 3, 5
and 6 proteins in PC3 cells. About 50μg total cellular lysate protein was
used for immunoblotting with antibodies to phospho-Smad (p-Smad)
-2 (60kDa; lane 1), -3 (52 kDa; lane 2), -5 (60kDa; lane 3) and -6 (62kDa;
lane 4). Blots were reprobed with an antibody to GAPDH after stripping.
Phosphorylation of 2, 3, and 5 was observed in PC3 cells. However,
Smad- 5 phosphorylation is significantly more than Smad-2 and 3 (lanes
1 and 2). Phosphorylation of Smad-6 is really negligible or not
observed.Abbreviations
PKC: Protein kinase C; TMA: Tissue microarray; RANKL: Receptor activator of
NFκb ligand; SMID: Smad interacting domain; Chip: Chromatin
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